Tagged with innovation,

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

technology transfer The National Scientific and Technical Research Council (CONICET) is the main organization in charge of the promotion of science and technology in Argentina. Santiago Villa and Marian Berenstein, general manager and general coordinator at CONICET’s tech transfer office, discuss the challenges of innovation in Argentina and the organization’s place on the…

basic research Manuel Díaz-Rubio, honorary president of Spain’s Royal Academy of Medicine, traces the history of Spain’s medical community over the last few decades, and emphasizes the importance of the pharmaceutical industry to the careers of doctors and physicians across the world.   You were head of Hospital San Carlos’ gastroenterology unit…

innovation Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives.   What are the objectives of the Royal Academy of Medicine and what are your own personal objectives as president? In order to answer this question we have to go back to…

consumer healthcare GSK’s Consumer Healthcare’s regional manager for the southern cone discusses the countries longstanding commitment to the Argentinian consumer and how this history allows them to succeed in a country typically dominated by strong domestic brands.   There was recently a wave of M&A in Chile and elsewhere, do you see this…

family business Adrian Fernandez, current CEO, shares his experience of taking a domestic company international and the viability of the family business model in the contemporary market.   As a rapidly internationalizing company, how much of a burden have regulatory barriers between countries placed on your business? Its not too much of…

medtech Margarita Alfonsel, general secretary of the Spanish Federation of Healthcare Technology Companies (FENIN), discusses the state of the medtech sector in Spain today, outlining the industry’s biggest priorities and areas of improvement.   The medical technology industry in Spain has a market size of EUR 6.8 million. As General Secretary…

innovation Javier Anitua, Managing Director of Mylan Spain, discusses the preservation of Spain’s pharmacy model, preventive solutions for pharmacists, and the need for higher generic penetration in Spain.   What more needs to be done in Spain to communicate the value that generics bring to stakeholders who set prices? The sustainability…

science Maria Luisa Poncela has been the General Secretary of Science, Technology and Innovation under the Spanish Ministry of Economy since January 2012. In her role she fosters business competitiveness and technology transfer across different sectors and regions, and in an exclusive interview with PharmaBoardroom she outlines some of the key…

biotech For many years, Spain’s biotechnology sector was lagging behind the powerhouses of countries like the US and UK. Today, the sector touts a significantly different story, due to strategic investments by Spain’s government. Regina Revilla, president of Spain’s biotech association ASEBIO, details the history of biotech in Spain and outlines…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…